Literature DB >> 17638515

Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.

Helen Steed1, Michael B Sawyer.   

Abstract

Paclitaxel is widely used in many cancers including ovarian, breast, lung, head and neck and primary unknown. Paclitaxel is extensively metabolized by cytochrome P450s and excreted in bile. The cytochromes involved include 2C8 and 3A4. This is a review of the pharmacokinetics, pharmacodynamics, drug interactions, metabolism and pharmacogenomics of paclitaxel.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17638515     DOI： 10.2217/14622416.8.7.803

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  9 in total

1.  Combination of Cl‑IB‑MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR‑dependent autophagy and mitotic catastrophe on human melanoma cells.

Authors:  Ana S Soares; Vera M Costa; Carmen Diniz; Paula Fresco
Journal:  J Cancer Res Clin Oncol       Date:  2014-06       Impact factor: 4.553

2.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

3.  Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.

Authors:  M F Kozloff; L P Martin; M Krzakowski; T A Samuel; T A Rado; E Arriola; J De Castro Carpeño; R S Herbst; J Tarazi; S Kim; B Rosbrook; M Tortorici; A J Olszanski; R B Cohen
Journal:  Br J Cancer       Date:  2012-09-18       Impact factor: 7.640

4.  Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.

Authors:  L P Martin; M F Kozloff; R S Herbst; T A Samuel; S Kim; B Rosbrook; M Tortorici; Y Chen; J Tarazi; A J Olszanski; T Rado; A Starr; R B Cohen
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

5.  Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.

Authors:  Li Chen; Ciao-Sin Chen; Yihan Sun; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-05       Impact factor: 3.288

6.  Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines.

Authors:  Yongjun Wang; Dan Liu; Qingchuan Zheng; Qiang Zhao; Hongjuan Zhang; Yan Ma; John K Fallon; Qiang Fu; Matthew T Haynes; Guimei Lin; Rong Zhang; Dun Wang; Xinggang Yang; Linxiang Zhao; Zhonggui He; Feng Liu
Journal:  Nano Lett       Date:  2014-09-07       Impact factor: 11.189

7.  Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.

Authors:  Q Fu; Y Wang; Y Ma; D Zhang; J K Fallon; X Yang; D Liu; Z He; F Liu
Journal:  Sci Rep       Date:  2015-07-13       Impact factor: 4.379

8.  In Vitro Anti-Tubulin Activity on MCF10A Cell Line and In Silico Rigid/Semiflexible-Residues Docking, of Two Lignans from Bursera Fagaroides var. Fagaroides.

Authors:  Verónica Rodríguez-López; César Millán-Pacheco; Judith González-Christen; Maricruz Anaya-Ruíz; Omar Aristeo Peña-Morán
Journal:  Molecules       Date:  2021-10-12       Impact factor: 4.411

9.  Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.

Authors:  Yoon-Sok Chung; Ho Chul Kang; Taeyong Lee
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.